Henning Wege

5.4k total citations
64 papers, 1.8k citations indexed

About

Henning Wege is a scholar working on Hepatology, Molecular Biology and Oncology. According to data from OpenAlex, Henning Wege has authored 64 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hepatology, 22 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Henning Wege's work include Hepatocellular Carcinoma Treatment and Prognosis (24 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Telomeres, Telomerase, and Senescence (10 papers). Henning Wege is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (24 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Telomeres, Telomerase, and Senescence (10 papers). Henning Wege collaborates with scholars based in Germany, United States and Italy. Henning Wege's co-authors include Ansgar W. Lohse, Björn Nashan, Kornelius Schulze, Mark Α. Zern, Klaus Pantel, Sabine Riethdorf, Johann von Felden, Tim H. Brümmendorf, Christin Gasch and Katharina Staufer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Henning Wege

59 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henning Wege Germany	20	660	526	431	430	345	64	1.8k
Chiara Raggi Italy	24	924 1.4×	681 1.3×	640 1.5×	329 0.8×	563 1.6×	54	1.9k
Eliza Wiercinska Germany	22	1.1k 1.7×	788 1.5×	210 0.5×	381 0.9×	316 0.9×	41	2.1k
Abha Khanna United States	12	764 1.2×	761 1.4×	504 1.2×	219 0.5×	402 1.2×	28	1.8k
Tatsuo Shimura Japan	27	928 1.4×	827 1.6×	675 1.6×	274 0.6×	292 0.8×	144	2.5k
Raleigh D. Kladney United States	23	996 1.5×	505 1.0×	111 0.3×	219 0.5×	434 1.3×	33	1.8k
Pedram Kharaziha Sweden	14	795 1.2×	201 0.4×	240 0.6×	175 0.4×	427 1.2×	25	1.4k
Kenta Yoshiura Japan	14	863 1.3×	298 0.6×	297 0.7×	524 1.2×	169 0.5×	34	1.8k
Xiaoshun He China	23	1.6k 2.4×	339 0.6×	511 1.2×	579 1.3×	982 2.8×	115	2.6k
Robert C. Huebert United States	26	841 1.3×	248 0.5×	715 1.7×	1.1k 2.5×	227 0.7×	46	2.3k
Hideo Shimura Japan	22	550 0.8×	383 0.7×	519 1.2×	424 1.0×	199 0.6×	61	1.5k

Countries citing papers authored by Henning Wege

Since Specialization

Citations

This map shows the geographic impact of Henning Wege's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henning Wege with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henning Wege more than expected).

Fields of papers citing papers by Henning Wege

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henning Wege. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henning Wege. The network helps show where Henning Wege may publish in the future.

Co-authorship network of co-authors of Henning Wege

This figure shows the co-authorship network connecting the top 25 collaborators of Henning Wege. A scholar is included among the top collaborators of Henning Wege based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henning Wege. Henning Wege is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zapf, Antonia, Ann‐Kathrin Ozga, Ali Canbay, et al.. (2024). Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) – a multicenter, randomized, controlled, open-label investigator-initiated trial. BMC Cancer. 24(1). 931–931. 2 indexed citations

Wege, Henning, Claudia Campani, Ruben H. de Kleine, et al.. (2024). Rare primary liver cancers: An EASL position paper. Journal of Hepatology. 81(4). 704–725. 4 indexed citations

Saborowski, Anna, Jaewon Hyung, Il Hwan Kim, et al.. (2024). 58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials. Annals of Oncology. 35. S235–S235.

Casar, Christian, Thomas Renné, Asmus Heumann, et al.. (2023). EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma. Scientific Reports. 13(1). 20827–20827. 10 indexed citations

Wege, Henning, Kornelius Schulze, Johann von Felden, Julien Caldéraro, & María Reig. (2021). Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. European Journal of Medical Genetics. 64(11). 104313–104313. 19 indexed citations

Fründt, Thorben, Dominik Nörz, Thomas Theo Brehm, et al.. (2021). Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. PLoS ONE. 16(12). e0258450–e0258450. 2 indexed citations

Felden, Johann von, Harald Ittrich, Thorben Fründt, et al.. (2020). Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. Visceral Medicine. 37(2). 87–93. 7 indexed citations

Krause, Jenny, Johann von Felden, Christian Casar, et al.. (2020). Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype. BMC Cancer. 20(1). 1130–1130. 18 indexed citations

Wege, Henning, et al.. (2018). Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma—correlation with liver cancer and liver cirrhosis. Analytical and Bioanalytical Chemistry. 410(30). 7965–7977. 15 indexed citations

10.

Kirstein, Martha M., Torsten Voigtländer, Nóra Schweitzer, et al.. (2017). Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterology Journal. 6(2). 238–246. 16 indexed citations

11.

Wolf, Janina, Georg H. Waetzig, Athena Chalaris, et al.. (2016). Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling. Journal of Biological Chemistry. 291(31). 16186–16196. 75 indexed citations

12.

Vogel, Arndt, Henning Wege, Karel Caca, Björn Nashan, & Ulf P. Neumann. (2014). The Diagnosis and Treatment of Cholangiocarcinoma. Deutsches Ärzteblatt international. 111(44). 748–54. 31 indexed citations

13.

Cornils, Kerstin, Kornelius Schulze, Boris Fehse, et al.. (2014). Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis. Oncogene. 34(3). 364–372. 27 indexed citations

14.

Hartjen, Philip, Bastian Höchst, Andrea Baier, et al.. (2013). The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity. Cellular & Molecular Biology Letters. 18(3). 447–58. 3 indexed citations

15.

Wege, Henning, et al.. (2011). Forced Activation of β-Catenin Signaling Supports the Transformation of hTERT -Immortalized Human Fetal Hepatocytes. Molecular Cancer Research. 9(9). 1222–1231. 13 indexed citations

16.

Brassat, Ute, Stefan Balabanov, Judith Dierlamm, et al.. (2010). Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL–positive CML cells. Experimental Hematology. 39(1). 66–76.e2. 25 indexed citations

17.

Benten, Daniel, Gunhild Keller, Alexander Quaas, et al.. (2009). Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model. Neoplasia. 11(9). 934–944. 56 indexed citations

18.

Fuchs, Sigrid, et al.. (2007). Absence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes. Cancer Letters. 256(1). 120–127. 8 indexed citations

19.

Wege, Henning, Hai Thanh Le, Li Liu, et al.. (2003). Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology. 124(2). 432–444. 134 indexed citations

20.

Wege, Henning. (2002). SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Research. 31(2). 3e–3. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact